NEO Director Kelly Michael Aaron purchased 5.0K shares at $7.60; stock now $7.42, -60.1% from 52-week high.
Kelly Michael Aaron, a director of NeoGenomics, purchased 5,000 shares at $7.60 on May 27, 2025, establishing an initial position in the company. The transaction occurred when NEO was trading 60.1% below its 52-week high of $18.61 and has since declined further to $7.42, representing a -25.6% decline over 30 days. The company is currently unprofitable with a net loss of $-25.9M in the latest quarter despite revenue of $168.0M and year-over-year growth of 11.6%, which limits the ability to assign strong directional conviction to the purchase. The modest initial position size (5.0K shares post-transaction, zero prior holdings) in the context of significant recent price deterioration and negative earnings warrants monitoring of whether additional accumulation or further transactions occur.